Acknowledgement to Referees

Acknowledgement to Referees Drugs (2017) 77:1929–1933 https://doi.org/10.1007/s40265-017-0845-7 Springer International Publishing AG, part of Springer Nature 2017 Dear Reader As we reach the final issue of Drugs for 2017, I wish to reflect on another successful year’s achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content. 2017 was a successful year for Drugs. Over 150 articles have been published, and as of the end of October, 28 of these have been downloaded from SpringerLink over 1000 times. Topics covered by these popular articles included the language of biosimilars, targeting of new signalling pathways in asthma, immune disorders and cancer, appropriate use of anti- epileptics, proton pump inhibitors and antimicrobials, chimeric antigen receptor (CAR)-T cells, nanobiotechnology in pain management, and new developments in the drug treatment of diabetes, psoriasis and hepatitis B. Social media sharing of information is becoming more important and is another metric with which to measure the reach of articles. This year several articles published in Drugs scored over 20 on the Altmetric system. The quality of articles published in the journal is also reflected in its most recent (2016) impact factor of 5.000 (up from 4.883 in 2015). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs Springer Journals

Acknowledgement to Referees

Drugs , Volume 77 (18) – Nov 10, 2017
Loading next page...
 
/lp/springer_journal/acknowledgement-to-referees-KcsffH6KeW
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
0012-6667
eISSN
1179-1950
D.O.I.
10.1007/s40265-017-0845-7
Publisher site
See Article on Publisher Site

Abstract

Drugs (2017) 77:1929–1933 https://doi.org/10.1007/s40265-017-0845-7 Springer International Publishing AG, part of Springer Nature 2017 Dear Reader As we reach the final issue of Drugs for 2017, I wish to reflect on another successful year’s achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content. 2017 was a successful year for Drugs. Over 150 articles have been published, and as of the end of October, 28 of these have been downloaded from SpringerLink over 1000 times. Topics covered by these popular articles included the language of biosimilars, targeting of new signalling pathways in asthma, immune disorders and cancer, appropriate use of anti- epileptics, proton pump inhibitors and antimicrobials, chimeric antigen receptor (CAR)-T cells, nanobiotechnology in pain management, and new developments in the drug treatment of diabetes, psoriasis and hepatitis B. Social media sharing of information is becoming more important and is another metric with which to measure the reach of articles. This year several articles published in Drugs scored over 20 on the Altmetric system. The quality of articles published in the journal is also reflected in its most recent (2016) impact factor of 5.000 (up from 4.883 in 2015).

Journal

DrugsSpringer Journals

Published: Nov 10, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off